CEO Crowley: Amicus will go it alone on migalastat Phase III success
This article was originally published in Scrip
Executive Summary
Amicus Therapeutics proved to investors on 20 August that the confidence it held in its lead Fabry disease drug candidate was valid, announcing positive results from its second Phase III trial of migalastat. Now a long regulatory road is ahead of the small New Jersey biotech firm, but CEO John Crowley says to "stay tuned."